Predictors of cardiovascular diseases among people living with HIV initiated on antiretroviral therapy in Khomas region, Namibia: A cross-sectional study

Roswitha Mahalie,1 Penehafo Angula,2 Kabwebwe Honoré Mitonga,2 Olanrewaju Oladimeji1

1Olympia, Windhoek, Namibia; 2School of Public Health: Oshakati Campus; Faculty of Health Sciences; University of Namibia, Namibia; 3Department of Public Health, Faculty of Health Science, Walter Sisulu University, Eastern Cape, South Africa

Abstract

Cardiovascular diseases (CVDs) have been identified as the leading cause of morbidity and mortality among people living with human immunodeficiency virus (PLHIV). However, it is evident that there is a lack of effective surveillance and monitoring of CVDs. Salient side-effects of antiretroviral therapy (ART) exacerbate pre-existing co-morbidities, hence the need for CVDs and its predictors to be monitored closely to ensure life-long care. Personal health records play a crucial role in the field of health information extraction because of their factuality and reliability.

The current study assessed the predictors associated with CVDs among PLHIV initiated on ART in the Khomas health district in Namibia.

A cross-sectional quantitative descriptive study was conducted to extract CVDs predictors from 529 patient care booklets (PCBs) between 2004 and 2018 at purposefully selected health facilities in Khomas health district. Data was matched with the electronic Patient Monitoring System (ePMS) and statistical analyses were performed. The study found that prominent CVDs predictors were found to be greatly prevalent among PLHIV initiated on ART with an adjusted variation (p<0.001). The mean ± SD age of all participants was 38.10, ± range 64 and 55.1% of them were males and 44.9% were females. Data from this study suggest that high blood pressure, obesity, smoking, and alcohol use are greatly prevalent among PLHIV, particularly among males. Systems that provide accurate information, early screening with subsequent treatment for PLHIV, is recommended by this study.

Introduction

Cardiovascular diseases (CVDs), the leading cause of death globally (31%) and in Africa (11.3%), has recently been recognized as an important cause of morbidity and mortality among people living with human immunodeficiency virus (PLHIV).1-5 The improved survival rate of PLHIV, and the changing HIV disease patterns, resulted in a growing burden of multi-morbidity.6 Crucially, the changing landscape of HIV clinical care, as recent evidence suggests that HIV-associated inflammation and immune activation are important mediators of cardiovascular risks globally, contributing to at least 84% of PLHIV diagnosed with one non-communicable disease (NCD) by 2030.7 HIV programmes, which are the first large-scale chronic disease initiatives in low-and-middle-income countries (LMICs), posit to be an ideal springboard to emulate and expand innovative tools and approaches to using data associated with CVDs risk factors that enhances the quality of life of PLHIV8 through measurement of tangible health outcomes. Accurate and up-to-date epidemiological data,9 are leveraged to positively identify gaps while influencing the future patterns, the burden and health outcomes of CVDs in the African region.10 A study conducted by Bogorodskaya, Chow and Triant established that there is a greater risk of CVDs in the long-term use of Antiretroviral therapy (ART).11 The authors further signified a strong association between an aging HIV infected population with multiple comorbidities and its vulnerability to CVDs. The prevalence of NCDs among HIV-infected persons in LMICs, hypertension, hypercholesterolemia, and obesity were among the most prevalent risk factors.6,11,12 The authors also found that although few NCD-HIV integrat-ed programs with screening and management approaches exist in resource limited settings, efficacy of such integration is not well-established.11,12 The introduction of prevention, screening, diagnosis, and treatment programmes in support with international recommendations are advocated for.

Eliminating shared risk factors such as tobacco use, unhealthy diet, physical inactivity and the abuse of alcohol could prevent up to 80% of heart diseases, type 2 diabetes and some cancers.11 The enforcement of synergistic legislation which are good progress markers on reducing the prevalence of NCDs is suggested by several authors.2,11-15 Numerous studies have shown that the determining risk factors for CVDs at the initiation of ART, enhances integrated interventions subsequently.7,16,17 Admittedly, local health systems are not adequately prepared to respond to the growing CVD burden by particularly identifying risk factors when clients are screened,18 enrolled or initiated into long-term ART care. In the Namibian context, a literature search could not provide any epidemiological evidence on the risk and prevalence of multiple comorbidities with special emphasis on...
CVDs among PLHIV, thus the current study was conducted to assess the prevalence of risk factors associated with CVDs.

Materials and methods

This cross-sectional quantitative descriptive study excluded patients who were enrolled prior to January 2004 and after 2017 from the study. Health risk factors such as blood pressure, body mass index (BMI), tobacco and alcohol use were extracted from the Patient Care Booklets (PCBs) of 529 clients using a tailor-made data extraction tool. Socio-demographic and programme data such as age,19 sex, marital status, blood pressure,20 overweight/obesity were matched with the electronic patient monitoring system (ePMS) as independent variables. The BMI, smoking and alcohol usage could not be used as the only standalone measure of risk factors for CVDs. Thus, a proven risk of developing CVDs were postulated accordingly.20

Combination of overweight, smoking, alcohol use and at least one elevated or stage 1 hypertension. Combination of obesity, smoking, alcohol use and at least one elevated, stage 1 or stage 2 hypertension. At least one elevated, stage 1 or stage 2 hypertension.

The case definition for hypertension was found to be the only well-defined predictor for CVDs at ART clinics. Hence, the reason why hypertension was used as the predominant variable to compare with other predictors and co-variates. The criteria for hypertension endorsed by the American College of Cardiology and American Heart Association (ACC/AHA) were used to classify hypertension as follows:

Elevated blood pressure: Systolic BP (SBP) 120-129 mmHg or diastolic BP (DBP) < 80 mmHg.

Stage 1 high blood pressure: SBP 130 to 139 mmHg or DBP 80 to 89 mmHg.

Stage 2 high blood pressure: SBP ≥140 mmHg or DBP ≥90 mmHg.21

The classification on accurate measurements and average of ≥2 readings on different occasions,21 as recorded in the PCB.

Variables like weight and height were extracted to determine BMI and subsequently examine the impact of obesity among PLHIV. Overweight as denoted by a BMI of 25 or above whilst 30 or above was categorised as obese.

Data analysis

Client records were reviewed for risk factor data recorded in the PCB. The extracted data was entered into IBM (R) SPSS version 25 to perform statistical analyses. Data was described using frequencies and proportions and summarised in tables and figures. Bivariate and multivariate analyses was performed by constructing two by two tables for each potential risk factor outcome. Socio demographic characteristics were tabulated by age and sex.

Ethical considerations

The Institutional Research and Ethics Committee of University of Namibia in the faculty of Health Sciences and the Namibian Ministry of Health and Social Services approved the study under reference number 17/3/3RM. The clients’ name, residential address, contact details, and any other variable that had the potential of breaching confidentiality were not included in the data extraction tool. The study conformed with the principles outlined in the World Medical Association Declaration of Helsinki.

Results

This study found that majority of the CVDs risk factors were greatly prevalent among PLHIV initiated on ART with an adjusted variation(p<0.001) as depicted in Table 1. Of the 529 records extracted for PLHIV initiated on ART, 55.1% were male whilst 44.9% were female with a median ± SD age of 38.10 years.

The study sought to analyse the association between sex and blood pressure. There was no evidence of a significant relationship between sex and high systolic blood pressure (Pearson Chi Square test 4.315, p-value of 0.365; Likelihood ratio test 4.271: p-value of 0.371) and high diastolic blood pressure (Pearson Chi Square test 1.824: p-value of 0.402; Likelihood ratio test 1.838: p-value of 0.399) among PLHIV.

The age of the patients was categorised between 1-10; 11-20; 21-30; 31-40; 41-50; 51-60; and 61+ years. There was no evidence of a significant relationship between age and high systolic blood pressure (Pearson Chi Square test at 29.385, p-value 0.260) and high diastolic blood pressure (Pearson Chi Square test at 11.466, p-value 0.489) among PLHIV which indicate a p-value >0.05. However, age and BMI were found to be greatly significant with a p-value of 0.018.

In addition, the study found that a positive relationship exists between BMI and high systolic blood pressure (Pearson Chi Square test 164.911; Likelihood ratio test 162.295) and high diastolic blood pressure risk (Pearson Chi Square test 62.864; Likelihood ratio test 65.121) with a p-value of 0.001 which is <0.05 threshold or 95% confidence level.

The findings of the study revealed that there is a significant association between alcohol consumption and risk of high systolic blood pressure. The Pearson Chi Square test (77.802) and the Likelihood ratio test (79.902) both shows a p-value of 0.001 which is <0.05 significant threshold.

Findings of the study proved that patient drop-out from ePMS was significantly associated with high blood pressure status (Pearson Chi Square test 16.737; Likelihood ratio test 17.087) which shows a p-value of 0.001 that is <0.05 significant threshold.

Furthermore, the study wanted to determine the association between a patient who is active in ePMS or those who are lost from the system either through death, transfer-out or lost-to-follow-up, and increased BMI. Both the Pearson Chi Square test (31.950) and Likelihood ratio test (31.708) shows a p-value of 0.001, respectively which is <0.05 significant threshold.

A significant relationship was found between the last ART status and alcohol consumption since the Pearson Chi Square test (6.713) shows a p-value of 0.035, and a Likelihood ratio(6.917) which presented with a p-value of 0.031. Both tests are above the threshold of <0.05 significance level.

Furthermore, it was found there is no significant association between sex and viral load, denoting that male and female viral load is random as the p-value of 0.767523 is greater than the threshold of <0.05 significance level. The Wald test result of a p-value of 0.5663 confirms that sex is not a good predictor of viral load (Table 2).

Lastly, age category, WHO clinical staging, blood pressure, alcohol consumption, smoking, body mass index, CD4 counts, ART regimens and duration on ART are significantly associated with viral load as the p-values are less than 0.05. The Wald test also confirm the significance of these predictors as shown in Tables 2 and 3.

Discussion

The study found that even though hospital-based information on morbidity and mortality of recent CVDs are readily available, similar data that is linked to individual PLHIV initiated on ART could not be found. All HIV uninfected individuals were excluded from the study and thus not used as controls.
High blood pressure, obesity, smoking, and alcohol use were found to be greatly prevalent among PLHIV initiated on ART in this study. These findings are in line with WHO, which suggests that NCDs are largely presentable by the reduction of their four main behavioural risk factors: tobacco use, harmful use of alcohol, unhealthy diet and physical inactivity.

Gender is one of the important socioeconomic determinants of health. Several studies have revealed that women are more vulnerable to the risk of obesity, heart diseases and stroke compared to men. In addition, female gender (AOR 2.12; 95% CI 1.45–3.11) was significantly associated with comorbidity risk by Magodoro, Esterhuizen and Chivele among adults living with HIV in Zimbabwe in 2016. On the contrary, this study revealed that more males (56%) are at risk of elevated risk of high systolic blood pressure compared to females. Notwithstanding, this finding is contrary to study findings conducted in South Africa and India where more females were found to be disproportionately affected by NCDs compared to males. Interestingly, Anish also found that systolic blood pressure, fasting blood sugar, and low-density lipoprotein were found to be significantly lower in Indian women.

The current study found that 40.5% of the patients between the ages of 41-50 years enrolled in the ART programme are at risk of stage 2 systolic blood pressure. On the other hand, 39.4% and 32.3% of the patients between the age group 41-50 years have been classified as high risk and optimal risk for raised diastolic blood pressure, respectively. Findings of the study such as increased prevalence of high blood pressure, obesity, smoking and alcohol use among PLHIV initiated on ART concur with Bogorodskaya et al., who postulated that an increase in age is a critical determinant of traditional risk factors and the role it plays in relation to CVD events. Several studies revealed similar trends in Africa and globally.

The study also established a significant association (p-value of 0.001) between BMI and raised blood pressure. These results concur with Anspree et al. who found that obesity (BMI>30 kg/m²) was the only risk factor that increased the odds of having an uncontrolled BP in hypertensive patients (p=0.02) after adjusting for age, gender, smoking status, alcohol use and HIV status. Critical lifestyle modification is required to reduce the prevalence of CVDs among PLHIV initiated on ART who are smoking tobacco products.

Twenty percent (20%) of those patients who are active in ePMS, showed a great statistical significance(p-value of 0.001) between alcohol use and smoking of tobacco products which requires strict enforcement of regulations on tobacco smoking and the mushrooming of illegal shebeens in Namibia. The results of this study are contrary to several other studies which indicated that alcohol use and smoking did not increase the risk of uncontrolled BP.

Incidentally, peer reviewed studies focussing on blood pressure estimates in PLHIV initiated on ART and untreated HIV negative controls revealed that HIV infection was associated with lower SBP, while treatment was associated with higher lipid levels in Sub-Saharan Africa. However, this study could not establish the prevalence of hypertensoin as a major risk factor leading to CVDs among PLHIV initiated on ART, suggesting that future studies measure the association of biomarkers of metabolic risks in the prediction of CVDs at health facility level.

Furthermore, the study revealed that patients who were enrolled in the ART programme and sampled for this study, had a mean follow-up day of 75.52% with a relatively low number of visits per annum which is reflected at 3.45%. Similar studies conducted in Eswatini (42%) and Cameroon (22.7%) demonstrated a slightly higher rate of follow-up days with a 16.3% loss to follow-up rate per annum.

There is overwhelming evidence from the study findings that sex is not associated with viral load and CVDs. It was also found that all the other predictors such as age category, WHO clinical staging, blood pressure, alcohol consumption, smoking, body mass index, CD4 count, ART regimens and duration on ART have a significant influence on the viral load and consequently leading to CVDs. The current findings are contrary to a study conducted by Niwaha et al., who could not find notable differences in the odds of hypertension by CD4 count, viral load, or ART among HIV positive individuals in this sample. At the time of data collection, the majority of the patients (53.67%) were on ART therapy for more than 2 years, specifically on first-line regimens such as TDF+3TC+NVP (38.19%), TDF/FTC/EFV(1F) (14.12%) and TDF/FTC/EFV (8.8%) respectively. However, with the advent of ‘Test and Treat’ in 2019, early diagnosis and targeted management of CVDs among PLHIV initiated on ART were optimised. This may address challenges identified in prototype inhibitors (PI) containing regimens while changing to Dolutegravir (DTG) which is more tolerable and effective for PLHIV initiated on ART.

Table 1. Summary of association between CVDs risk factors (n=529).

| Independent variable (chi squares) | High Systolic Pressure | Overweight /Obesity | Alcohol | Smoking | Poor data recording | True retention |
|-----------------------------------|------------------------|---------------------|---------|---------|---------------------|---------------|
| Sex (1.59)                        | 0.478                  | (0.513)             | 0.474   | (0.752)  | 0.386               | 0.290         |
| Age (0.727)                       | 0.394                  | (5.557)             | 0.018   | (0.382)  | 0.536               | 0.317         |
| Marital status (15.006)           | 0.048                  | (0.318)             | 0.073   | (0.014)  | 0.907               | 0.392         |
| Blood pressure (164.911)          | 0.001                  | (32.042)            | 0.001   | (1.686)  | 0.194               | 0.123         |
| Overweight/obesity (164.911)     | 0.001                  | (32.042)            | 0.001   | (1.686)  | 0.194               | 0.123         |
| Alcohol (77.802)                  | 0.001                  | (0.157)             | 0.001   | (0.966)  | 0.124               | 0.050         |
| Smoking (70.888)                  | 0.001                  | (0.573)             | 0.001   | (0.966)  | 0.124               | 0.050         |
| Poor data recording (80.630)      | 0.001                  | (51.014)            | 0.001   | (2.372)  | 0.124               | 0.050         |
| Follow-up days (1.248)            | 0.490                  | (1.065)             | 0.015   | (2.559)  | 0.278               | 0.297         |
| True retention (16.737)           | 0.001                  | (31.950)            | 0.001   | (2.585)  | 0.108               | 0.421         |
| Last ART status (4.335)           | 0.001                  | (1.849)             | 0.397   | (6.715)  | 0.055               | 0.246         |

*P-value Pearson chi-square test statistically significant at 0.05.
Table 2. Summary of association between CVDs risk factors and viral load.

| Characteristic | Total | Viral Load: Low Level Viremia | P-value* |
|---------------|-------|-------------------------------|----------|
|               | No    | Yes                           |          |
| **Sex**       |       |                               |          |
| Female        | 313   | 316 (60.9%)                   | 177 (57.8%) | 0.767523 |
| Male          | 216   | 214 (39.1%)                   | 129 (42.2%) |
| **Total**     | 529   | 490 (92.3%)                   | 206 (68.5%) |
| **Age Category** |     |                               |          |
| 0-17 years    | 4     | 2 (0.7%)                      | 2 (0.8%)  | 0.000   |
| 18-25 years   | 13    | 6 (2.2%)                      | 7 (2.5%)  |
| 25-45 years   | 122   | 66 (24.2%)                    | 56 (23.0%) |
| 45-65 years   | 146   | 54 (19.3%)                    | 92 (37.8%) |
| >65 years     | 231   | 145 (53.1%)                   | 86 (35.4%) |
| **Total**     | 516   | 273 (13.8%)                   | 243 (11.5%) |
| **WHO Clinical Staging** | |                               |          |
| 1             | 228   | 113 (49.3%)                   | 125 (53.9%) | 0.02216 |
| 2             | 23    | 10 (4.3%)                     | 13 (5.6%)  |
| 3             | 24    | 16 (6.9%)                     | 8 (3.3%)   |
| 4             | 4     | 1 (0.7%)                      | 3 (1.2%)   |
| **Total**     | 299   | 140 (46.8%)                   | 159 (51.8%) |
| **CVDs Predictors** | |                               |          |
| Blood Pressure |       |                               |          |
| Elevated (>120-129 or >130mmHg (d)) | 35 | 23 (6.6%) | 14 (4.4%) | 0.00 |
| Hypertension risk stage 2 (130-139 or 140-149mmHg (d)) | 52 | 48 (16.6%) | 7 (3.1%) | |
| Hypertension risk stage 3 (>140-149 and >150 mmHg (d)) | 77 | 42 (16.3%) | 35 (13.5%) | |
| Hypertension crises (>150 mmHg (s) or >180-110 mmHg (d)) | 4 | 4 (1.6%) | 0 (0.0%) | |
| Low BP (<90 (s) and <60(d)) | 14 | 13 (4.4%) | 1 (0.4%) | |
| No BP Recorded in (s) | 167 | 56 (15.4%) | 111 (35.9%) | |
| Normal BP (<120 and <80mmHg(d)) | 164 | 105 (36.3%) | 59 (20.0%) | |
| **Alcohol** |       |                               |          |
| No don’t drink alcohol | 128 | 104 (32.0%) | 34 (21.7%) | 0.02092 |
| Not Recorded in PCB | 226 | 139 (43.8%) | 87 (55.4%) | |
| Yes, don’t drink alcohol | 118 | 82 (25.2%) | 36 (22.9%) | |
| **Total** | 562 | 282 (23.0%) | 280 (51.7%) | |
| **Smoking** |       |                               |          |
| No don’t smoke any tobacco products | 254 | 206 (80.8%) | 93 (36.8%) | 0.00 |
| Not Recorded in PCB | 228 | 90 (34.2%) | 138 (54.3%) | |
| Yes, smoke tobacco products | 34 | 14 (4.7%) | 20 (7.6%) | |
| **Total** | 516 | 320 (62.1%) | 196 (37.9%) | |
| **Body Mass Index** | |                               |          |
| No height recorded in PCB | 140 | 39 (27.9%) | 101 (71.8%) | 0.00 |
| Normal weight (18.5-24.9) | 244 | 149 (60.8%) | 95 (38.0%) | |
| Not scaled | 3 | 1 (0.4%) | 2 (0.8%) | |
| Obese (>30) | 23 | 17 (7.2%) | 6 (2.5%) | 0.00 |
| Overweight (25.0-29.9) | 67 | 36 (13.2%) | 31 (13.2%) | |
| Underweight (<18) | 42 | 31 (11.4%) | 11 (4.5%) | |
| **CD4 Count** | |                               |          |
| <200 cells/mm³ | 21 | 21 (7.7%) | 0 (0.0%) | 0.00 |
| 200-500 cells/mm³ | 18 | 18 (6.8%) | 0 (0.0%) | |
| >500 cells/mm³ | 11 | 11 (4.0%) | 0 (0.0%) | |
| >500 cells/mm³ | 466 | 223 (31.7%) | 243 (100.0%) | |
| **Total** | 516 | 273 | 243 | |
| **ART regimen** | |                               |          |
| ARC+3TC+DTG | 2 | 2 (0.7%) | 0 (0.0%) | 0.00 |
| ARC+3TC/EFV | 90 (90) | 4 | 4 (1.4%) | 3 (1.2%) | |
| ARC+3TC/LPV + (90) | 4 | 4 (1.4%) | 0 (0.0%) | |
| AZT+3TC+3TC | 1 | 1 (0.4%) | 0 (0.0%) | |
| AZT+3TC/EFV | 1 | 1 (0.4%) | 0 (0.0%) | |
| AZT+3TC/EFV (1b) | 8 | 8 (2.9%) | 0 (0.0%) | |
| AZT+3TC/3TC (30 / 40) | 1 | 1 (0.4%) | 0 (0.0%) | |
| AZT+3TC/NVP (1a) / 4b | 16 | 16 (5.8%) | 14 (5.8%) | |
| AZT+3TC/ATV/r | 3 | 3 (1.1%) | 2 (0.8%) | |
| D4T+3TC/EFV (1d) | 2 | 2 (0.8%) | 0 (0.0%) | |
| D4T+3TC/NVP (1c) /4a | 3 | 3 (1.1%) | 0 (0.0%) | |
| TDF+3TC+DTG | 44 | 44 (15.8%) | 41 (16.4%) | |
| TDF+3TC+DTG/100 | 1 | 1 (0.4%) | 0 (0.0%) | |
| TDF+3TC+EFV | 10 | 10 (3.6%) | 9 (3.6%) | |
| TDF+3TC+EFV400 | 19 | 19 (6.8%) | 19 (7.8%) | |
| TDF+3TC+3TC | 199 | 199 (71.3%) | 5 (1.2%) | |
| TDF+3TC+EFV | 3 | 3 (1.1%) | 2 (0.8%) | |
| TDF+3TC/ATV/r | 6 | 6 (2.2%) | 0 (0.0%) | |
| TDF+3TC/EFV (1F) | 30 | 30 (10.8%) | 29 (11.5%) | |
| TDF+3TC/EFV | 1 | 1 (0.4%) | 0 (0.0%) | |
| TDF+3TC/ATV/r (1e) | 10 | 10 (3.6%) | 9 (3.6%) | |
| TDF+3TC/EFV (2a) | 1 | 1 (0.4%) | 0 (0.0%) | |
| TDF+3TC/3TC (30 / 40) | 2 | 2 (0.8%) | 0 (0.0%) | |
| TDF+3TC/ATV/r (90 / 60) | 46 | 46 (16.5%) | 44 (16.5%) | |
| TDF+3TC/EFV (90 / 00) | 1 | 1 (0.4%) | 0 (0.0%) | |
| TDF+3TC/EFV (99 / 00) | 10 | 10 (3.6%) | 10 (4.1%) | |
| TDF+3TC/EFV (99 / 00) | 13 | 13 (4.7%) | 11 (4.5%) | |
| TDF+3TC/EFV (1F) | 74 | 74 (26.6%) | 59 (23.4%) | |
| **Total** | 521 | 278 | 243 | |
| **Duration on ART (years)** | |                               |          |
| <2 years | 146 | 88 (22.9%) | 58 | 0.00 |
| >2 years | 126 | 90 (68.0%) | 36 | |
| **Total** | 272 | 178 | 94 | |
Table 3. Summary of the significance of CVDs risk factors in predicting viral load.

| Characteristic                  | Coefficient | Wald Chi-Square | OR 95 C.I | P-value* |
|--------------------------------|-------------|----------------|-----------|----------|
| (Intercept)                    | -0.198776   | 0.3875017      | 0.84366   | 0.446109 | 0.53362  |
| Sex                            |             |                |           |          |
| Female (Ref)                   |             |                |           |          |
| Male                           | 0.271975    | 21.51447       | 0.153557  | 0.390394 | 0.5663   |
| Smoking                        |             |                |           |          |
| Yes, don’t smoke tobacco products | -0.232779   | 0.6822887      | -0.80191  | 0.336531 | 0.00880  |
| No, don’t smoke any tobacco products | -0.280431   | 1.92030       | -0.93792  | 0.277056 | 0.00968  |
| Not Recorded in PCB            | -0.355039   | 1.422928       | -0.95855  | 0.249675 | 0.03292  |
| Blood Pressure                 |             |                |           |          |
| Hypertension risk stage 1 (130-139 or 89-99mmHg(d)) | 0.78867    | 30.19451       | 0.498812  | 1.078529 | 0.00000  |
| Hypertension risk stage 2 (>140-170 and ≥90 mmHg (d) | 0.768154   | 34.59375       | 0.504397  | 1.031911 | 0.00000  |
| Elevated (>120-129 or >80mmHg(d) | 0.291774    | 5.525152       | 0.041088  | 0.542466 | 0.1874   |
| Normal BP (<120 and <80mmHg(d)) | 0.765519    | 30.79211       | 0.485641  | 1.041398 | 0.00000  |
| Hypertension crises (>180 mmHg(s) or ≥90-110 mmHg (d) | 0.274983   | 1.452056       | -0.18588  | 0.735842 | 0.02820  |
| No BP Recorded in PCB          | 0.458446    | 16.54767       | 0.230845  | 0.686047 | 0.00005  |
| Alcohol                        |             |                |           |          |
| No don’t drink alcohol         | 0.055181    | 1.32156        | -0.04176  | 0.152122 | 0.05351  |
| Not Recorded in PCB            | 0.122916    | 0.9543502      | -0.13119  | 0.37702  | 0.02681  |
| Age category                   |             |                |           |          |
| 0-17 years                     | -0.172322   | 0.7527848      | -0.57343  | 0.228785 | 0.06560  |
| 18-25 years                    | 0.01585     | 0.01886101     | -0.21722  | 0.248921 | 0.00077  |
| 26-35 years                    | -0.092117   | 3.007171       | -0.1994   | 0.015162 | 0.00290  |
| 35-45 years                    | 0.017912    | 0.1539827      | -0.00092  | 0.116742 | 0.001434 |
| Body Mass Index (BMI)          |             |                |           |          |
| Normal weight (18.0-24.9)      | 0.052254    | 0.621706       | -0.08158  | 0.160993 | 0.03941  |
| Overweight (25.0-29.9)         | 0.071948    | 0.8382374      | -0.08676  | 0.230652 | 0.00990  |
| Obese (>30)                    | -0.04357    | 0.1819073      | -0.24988  | 0.162739 | 0.01974  |
| No height recorded in PCB      | 0.134245    | 3.06677        | -0.02057  | 0.289056 | 0.04991  |
| Not scaled                     | 0.028912    | 0.01618541     | -0.44344  | 0.503061 | 0.03876  |
| CD4 Count                      |             |                |           |          |
| < 200 cells/ mm³               | -0.021215   | 0.007050633    | -0.30599  | 0.281563 | 0.00308  |
| > 500 cells/ mm³               | 0.325156    | 6.983351       | 0.076663  | 0.573648 | 0.00823  |
| 200-350 cells/ mm³             | -0.008193   | 0.00286252     | -0.31744  | 0.301655 | 0.01733  |

*P-value Pearson chi-square test statistically significant at 0.05.

Limitations

The challenge of getting the right datasets for CVDs risk factor prediction is very important. The study findings revealed that missing and incomplete CVDs risk factor data from the PCBs and pEMS compromised the quality of care provided to PLHIV initiated on ART. Therefore, an integrated approach to ensure sound data management practices for better health outcomes was recommended to the Ministry of Health and Social Services.

Conclusions

The study highlights the high prevalence of CVD risk, lack of information of CVDs and its risk factors among PLHIV initiated on ART. Although statistical evidence posits that major predictor risk factors are significantly associated with viral load, more research is needed to gain understanding of the immune activation and inflammation markers to estimate the link between the predictor risk factors in PLHIV initiated on ART and CVDs. With the current epidemiological transition of HIV and CVDs, there is a need to advocate for systems that provide accurate information and early screening of CVDs for PLHIV initiated on ART.

References

1. Torpey K, Mastro TD. Discussion paper on how to promote the inclusion of the prevention and control of noncommunicable diseases within other programmatic areas. Who Gcm/Ned. 2016;1–25.
2. World Health Organization. Global Atlas on Cardiovascular Disease Prevention And Control. Policies, Strategies and Interventions. Iraq. 2011;164.
3. World Heart Federation. Urbanization and Cardiovascular Disease. World Hear Fed. 2012;1–3.
4. Nojilana B, Bradshaw D, Pillay-van Wyk V, Msembali W, Laubscher R, Somdyala NIM, et al. Emerging trends in non-communicable disease mortality in South Africa, 1997 – 2010. South Afr Med J 2016;106:477–84.
5. Atun R, De Jongh T, Secchi F, et al. A systematic review of the evidence on integration of targeted health interventions into health systems. Vol. 25, Health Policy and Planning. 2010. 1–14 p.
6. Haldane V, Legido-Quigley H, Chuaah FLH, et al. Integrating cardiovascular diseases, hypertension, and diabetes with HIV services: a systematic review. AIDS Care - Psychol Socio-Medical Asp AIDS/HIV 2018;30:103–15.
7. Ekriko UE, Akpan EE, Ekott JU, et al Prevalence and correlates of traditional risk factors for cardiovascular disease in a Nigerian ART-naive HIV population:
a cross-sectional study. 2018;1–9.
8. Rabkin M, El-Sadr WM. Why reinvent the wheel? leveraging the lessons of HIV scale-up to confront non-communicable diseases. Glob Public Health 2011;6:247–56.
9. Keates AK, Mocumbi AO, Ntsekhe M, et al. Cardiovascular disease in Africa: Epidemiological profile and challenges. Nat Rev Cardiol 2017;14:273–93.
10. Patel P, Rose CE, Collins PY, et al. Noncommunicable diseases among HIV-infected persons in low-income and middle-income countries: a systematic review and meta-analysis. 2018; May.
11. Bogorodskaya M, Chow FC, Triant VA. Stroke in HIV. Can J Cardiol 2019;35:280–7.
12. Opare J, Ohuabunwo C, Agongo E, et al. Improving surveillance for non-communicable diseases in the Eastern Region of Ghana - 2011. J Public Heal Epidemiol 2013;5:87–94.
13. Anda RF, Butchart A, Felitti VJ, Brown DW. Building a Framework for Global Surveillance of the Public Health Implications of Adverse Childhood Experiences. Am J Prev Med 2010;39:93–8.
14. Harries AD, Zachariah R, Kapur A, et al. The vital signs of chronic disease management. Trans R Soc Trop Med Hyg 2009;103:537–40.
15. Li Y, Wang L, Jiang Y, et al. Risk factors for noncommunicable chronic diseases in women in China: surveillance efforts. Bull World Health Organ 2013;91:650–60.
16. Ducimetie P, Leport C, Moal L, et al. Risk Factors for Coronary Heart Disease in Patients Treated for Human Immunodeficiency Virus Infection Compared with the General Population. 2003;37.
17. Nduka CU, Stranges S, Bloomfield GS, et al. A plausible causal link between antiretroviral therapy and increased blood pressure in a sub-Saharan African setting: A propensity score-matched analysis. Int J Cardiol. 2016.
18. Institute of Health Measurement. Namibia: State of the Nation’s Health Findings from the Global Burden of Disease. Seattle, WA; 2016.
19. Hyle EP, Bekker LG, Martey EB, et al. Cardiovascular risk factors among ART-experienced people with HIV in South Africa. J Int AIDS Soc 2019;22:1–9.
20. DeGuire J, Clarke J, Rouleau K, Joel Roy TB. Blood pressure and hypertension. Canada; 2019.
21. Carey RM, Whelton PK, Aronow WS, et al. Prevention, detection, evaluation, and management of high blood pressure in adults: Synopsis of the 2017 American College of Cardiology/American Heart Association Hypertension Guideline. Ann Intern Med 2018;168:351–8.
22. Patra S, Bhise MD. Gender differentials in prevalence of self-reported non-communicable diseases (NCDs) in India: evidence from recent NSSO survey. J Public Health 2016;24:375–85.
23. Gerber LH, Stout NL, Schmitz KH, Stricker CT. Integrating a prospective surveillance model for rehabilitation into breast cancer survivorship care. Cancer 2012;118:2201–6.
24. Guo F, Hsieh E, Lv W, et al. Cardiovascular disease risk among Chinese antiretroviral-naive adults with advanced HIV disease. BMC Infect Dis 2017;17:1–10.
25. Anish T, Shahulhameed S, Vijayakumar K, et al. Gender difference in blood pressure, blood sugar, and cholesterol in young adults with comparable routine physical exertion. J Fam Med Prim Care 2013;2:200.
26. Anshro B, Meyer I, Okello V, et al. Evaluation of NCD service integrated into a general MSF INTERNAL REPORT Evaluation of NCD service integrated into a general OPD and HIV service in Matsapha, Swaziland, 2017.
27. Magodoro IM, Esterhuizen TM, Chivese T. A cross-sectional, facility based study of comorbid non-communicable diseases among adults living with HIV infection in Zimbabwe. BMC Res Notes 2016;9:379.
28. World Health Organization. Guideline on when to Start Antiretroviral Therapy and on Pre-exposure Prophylaxis for HIV. WHO, Geneva, Switzerland, 2015.
29. Phalane E, Fourie CMT, Mels CMC, et al. A comparative analysis of blood pressure in HIVinfected patients versus uninfected controls residing in sub-Saharan Africa: a narrative review. J Hum Hypertens 2020. DOI:10.1038/s41371-020-0385-6. 19.
30. Niwaha AJ, Wosu AC, Kayongo A, et al. Association between Blood Pressure and HIV Status in Rural Uganda: Results of Cross-Sectional Analysis. Glob Heart 2021;16:12.